Technique combines BioTrove’s OpenArray nanofluidic PCR platform and Gene Express’ measurement standards.

BioTrove and Gene Express entered an exclusive comarketing agreement to test market a standardized genetic profiling test for indicators of lung cancer risk. Called the Standardized NanoArray PCR (SNAP) gene-expression profiling system, the method provides consistent and accurate lung cancer risk analysis deployable to diagnostic laboratories or community hospitals, according to the companies.

The SNAP system couples several high-complexity, multigene diagnostic tests into a diagnostic tool designed to accelerate and control PCR analysis of biomarkers for lung cancer risk, the collaborators add. The firms believe that this combination provides the same quality and dynamic range of standard real-time qPCR but with simplified workflow and reduced sample requirements.

“Our SNAP gene-expression profiling system simplifies and standardizes laboratory workflow as well as reduces reagent and sample requirements, making genetic profiling viable and translatable across diagnostic laboratories around the country and potentially around the world,” explains David Lester, Ph.D., CTO, Gene Express.

The profiling test specifically combines BioTrove’s OpenArray® nanofluidic PCR platform, Gene Express’ standards for accurate and consistent PCR measurement, and the expertise of the University of Rochester School of Medicine and Dentistry. The BioTrove OpenArray nanofluidic PCR platform enables large-scale analyses with minimal sample requirements. The OpenArray system allows scientists to conduct up to 3,072 independent PCR analyses simultaneously on up to 144 samples in a plate the size of a microscope slide, according to BioTrove. Gene Express’ standardized RT PCR (StaRT-PCR) standards method controls for false negatives and false positives and its TaqMan® fluorogenic-labeled probes enable specific detection of PCR products.

Previous articleFluidigm Gains Rights to Inventions for Detecting Fetal Genetic Characteristics in Maternal Plasma
Next articleEGFR Inhibitors Could Be Effective in Obese Breast Cancer Patients